Levetiracetam
Product Images NDC 10135-695

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 10135-695). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Following Structural Formula For Levetiracetam Usp, A Single Enantiomer, Is ( ) (s) α Ethyl 2 Oxo 1-pyrrolidine Acetamide, Its Molecular Formula Is C8h14n2o2 And Its Molecular Weight Is 170.21. Levetiracetam Is Chemically Unrelated To Existing Antiepileptic Drugs (aeds). (Levetiracetam Oral Solution Usp 01)

The Following Structural Formula For Levetiracetam Usp, A Single Enantiomer, Is ( ) (s) α Ethyl 2 Oxo 1-pyrrolidine Acetamide, Its Molecular Formula Is C8h14n2o2 And Its Molecular Weight Is 170.21. Levetiracetam Is Chemically Unrelated To Existing Antiepileptic Drugs (aeds). (Levetiracetam Oral Solution Usp 01)
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Oral Solution Usp 02)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Oral Solution Usp 02)
This appears to be a statistical report of a study on the effectiveness of Levetiracetam. It shows different percentages of effectiveness at different dosages compared to a placebo group. The asterisk indicates a statistically significant result.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Oral Solution Usp 03)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Oral Solution Usp 03)
The text appears to be a table containing percentages and statistical information related to a study involving a placebo and two doses of Levetiracetam (1000 mg/day and 2000 mg/day). However, the table is incomplete and lacks context for further interpretation.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Oral Solution Usp 04)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Oral Solution Usp 04)
This is a statistical data table comparing the effectiveness of a placebo and a medication called Levetiracetam at 3000mg/day among two groups (N = 104 and N = 180). The percentages listed above may represent the success rate of treatment or the reduction in symptoms. The asterisk (*) indicates that the Levetiracetam group had a statistically significant improvement over the placebo group. The meaning behind the two symbols (& o) is not clear without further context.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Oral Solution Usp 05)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Oral Solution Usp 05)
This is a graphical presentation of the percentage of patients on placebo and Levetiracetam. The Levetiracetam group showed statistically significant results compared to the placebo group.*
FDA Label Image

Figure 6: Responder Rate (≥ 50 % Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Oral Solution Usp 06)

Figure 6: Responder Rate (≥ 50 % Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Oral Solution Usp 06)
This is a statistical report of the percentage of patients who received either a placebo or levetiracetam and their corresponding effectiveness. The percentage of patients who responded positively to levetiracetam was 72.2% while only 45.2% responded positively to placebo. The report also states that the response to levetiracetam was statistically significant compared to the placebo group.*
FDA Label Image

Principal Display Panel (473 mL Bottle LabelNDC 10135-0695-08LevetiracetamOral Solution, USP100 mg/mLDispense accompanyingMedication Guideto each patient.Rx only16 fl oz (473 mL))

Principal Display Panel (473 mL Bottle LabelNDC 10135-0695-08LevetiracetamOral Solution, USP100 mg/mLDispense accompanyingMedication Guideto each patient.Rx only16 fl oz (473 mL))
This is a description of an oral solution drug called Levetiracetam which comes in a concentration of 100 mg/mL. The packaging contains the dosage instructions and safety warnings. The other texts seem to be either gibberish or inaccuracies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.